Gastric Ucer. gastric ulcer
Conditions
Interventions
Intervention 1: In intervention group (reverse hybrid group): patients in the first 7 days of treatment receive pantoprazole 40 mg, amoxicillin 1g, clarithromycin 500 mg, metronidazole 500 mg every 12
Treatment - Drugs
In intervention group (reverse hybrid group): patients in the first 7 days of treatment receive pantoprazole 40 mg, amoxicillin 1g, clarithromycin 500 mg, metronidazole 500 mg every 12 hours, and th
In control group: (14 days concomitant group): four drugs: pantoprazole 40 mg, amoxicillin 1g, clarithromycin 500 mg and metronidazole 500 mg every 12 hours for 14 days prescribed.
Sponsors
Technology Assistant, Mazandaran University Of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with endoscopic findings of gastric or duodenal ulcer or gastric and duodenal erosoin and have Helicobacter pylori infection ; patients older than 18 year and less than 80 years. Exclusion criteria : pregnancy and lactation ; previously received Helicobacter pylori therapy ; patients received PPI (poroton poup inhibitor) or H2 RA (histamine 2 receptor antagonist) in last 2 weeks or within 4 weeks who received antibiotics ; history of surgery on the stomach ; Patients with confirmed advanced disease , severe cardiac, pulmonary , endocrine , chronic renal failure, chronic liver disease or have cancer ; The consumption of alcoholic beverages
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori infection. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Upper GI endoscopy and biopsy for pathology and RUT for HP infection before intervention and endoscopy and biopsy or urea breath test and or stool examination for HP antigen for HP infection after intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| HP eradication rate and drug adverse effects and patients compliance in two groups. Timepoint: 12 weeks after initiation of therapautic regimens. Method of measurement: Urea breath test, stool exam for HP antigen and or endoscopy and biopsy. questionary assesment. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Mohammad Valizadeh Toosi
Gut and Liver research Center, Mazandaran University Of Medical Sciences
Outcome results
None listed